Clinical trials
Cardiomyopathies clinical trials
Below are recruiting cardiomyopathies clinical trials, each written for real people, not researchers. We’re tracking 322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07336290Enrolling by invitation
One-stop MRI for hypertrophic cardiomyopathy
This study uses a single, advanced heart MRI to get a complete picture of hypertrophic cardiomyopathy—a condition where the heart muscle is thickened. It aims to make diagnosis and treatment planning faster and easier for patients.
Ages Any age - NCT07336394Recruiting
Study on rare heart muscle diseases using advanced MRI
This study uses a special heart MRI to better diagnose and understand rare heart muscle diseases. It may help doctors predict risks and make more accurate treatment decisions.
BeijingAges Any age - NCT07325968Enrolling by invitation
Heart MRI Study for Myocarditis and Heart Inflammation
This study uses a special heart MRI to look closely at inflammation in the heart muscle. It helps doctors better understand and treat myocarditis and inflammatory cardiomyopathy.
Ages Any age - NCT07298044RecruitingPhase 4
Switching from tafamidis to acoramidis for heart amyloidosis
This study will see how switching from tafamidis to a newer medicine called acoramidis changes the level of a protein (called transthyretin) in your blood. The goal is to see if acoramidis might work better for people with this type of amyloidosis that affects the heart.
Sankt Pölten, Lower AustriaAges 18–90 - NCT07293338Recruiting
Heart muscle blood flow study for dilated cardiomyopathy
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
Hangzhou, ZhejiangAges 18 years+ - NCT07295613Enrolling by invitation
Registry of hypertrophic cardiomyopathy: regional features, genetics and course
This study is a registry that collects information about people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) to better understand how it affects different people and to study its genetic causes. By joining, you help researchers learn more about this condition and how it progresses.
Moscow, Moscow RegAges Any age - NCT05569382RecruitingPhase 4
Testing bisoprolol and verapamil in hypertrophic heart disease
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
Aarhus NAges 18 years+ - NCT07276139Recruiting
Heart device experience and outcomes study
This study collects information from people who have a heart device (like a pacemaker) to learn how these devices work in real life and how they affect patients. By joining, you help doctors improve care for future patients.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT06846086RecruitingPhase 3
Melatonin for heart muscle protection
This trial tests if adding melatonin to standard heart medication helps protect the heart muscle in people with cardiomyopathy. If you are stable on your current heart meds, you may be able to join.
Dakahlia, Egypt, MansouraAges 18 years+ - NCT07263204Recruiting
AI for diagnosing and predicting hypertrophic cardiomyopathy
This trial uses artificial intelligence to help diagnose and predict outcomes for people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes thickened. It may help doctors better understand your condition and plan your care.
Hangzhou, ZhejiangAges 18 years+ - NCT06898762Recruiting
National study on inflammatory heart disease for patients with symptoms
This study is creating a national registry to learn more about inflammatory myocardial disease (inflammation of the heart muscle). If you have symptoms like chest pain, shortness of breath, palpitations, or certain test results, you may be eligible to join and help advance research.
Murcia, MurciaAges 18 years+ - NCT07241104RecruitingPhase 1
Study of a new drug for dilated cardiomyopathy with a specific genetic change
This trial tests an experimental drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic mutation (R14del in the PLN gene). The goal is to see if the drug can improve heart function and symptoms.
AmsterdamAges 18–80 - NCT07240844RecruitingPhase 4
Enavogliflozin for amyloid heart disease
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
SeoulAges 19 years+ - NCT07235462Recruiting
Acoramidis for heart disease due to TTR amyloidosis
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
Multiple LocationsAges 18 years+ - NCT07218887RecruitingPhase 1/Phase 2
Gene therapy for BAG3-related heart failure
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
Birmingham, AlabamaAges 18–70 - NCT06741995Recruiting
Testing antibodies to predict heart muscle disease progression
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Wuhan, HubeiAges 18–75 - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Birmingham, AlabamaAges 18 years+ - NCT07202897RecruitingPhase 3
Preventing blood clots in hypertrophic cardiomyopathy with rivaroxaban
This trial tests if the blood thinner rivaroxaban can prevent strokes in people with hypertrophic cardiomyopathy who have early signs of damage in their left atrium (the heart's upper chamber). You may qualify if you have this condition, are in a normal heart rhythm, and are between 40 and 80 years old.
AngersAges 40–80 - NCT07150299Recruiting
How heart medications affect blood flow in hypertrophic cardiomyopathy
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
ViennaAges 18 years+ - NCT07137338RecruitingPhase 1
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
San Diego, CaliforniaAges 18–65 - NCT07110818Recruiting
Non-ischemic Cardiomyopathy Registry and Biobank
This registry study collects information, blood samples, and MRI images from people with non-ischemic cardiomyopathy (a heart muscle disease not caused by blocked arteries). By joining, you help researchers better understand the condition and find new ways to diagnose and treat it.
Montreal, QuebecAges Any age - NCT06948344Recruiting
Genetics study for inherited heart muscle disease
This study is looking for people with inherited heart muscle disease that may be genetic. It uses advanced genetic testing to better understand the cause.
SeoulAges 19 years+ - NCT07103655Enrolling by invitationPhase 4
Mavacamten for mid-to-apical obstruction in HCM
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
Hangzhou, ZhejiangAges 18–75 - NCT06935253Recruiting
AI to Improve Cardiology Care
This trial tests whether large language models (a type of AI that understands human language) can help cardiologists give better care. If you are a qualified cardiologist who currently treats patients, you may be eligible.
Palo Alto, CaliforniaAges 18 years+
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiomyopathies?
- Yes. Clin2 currently lists 322 recruiting cardiomyopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiomyopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.